10 June 2024

At AstraZeneca, we have the ambition to redefine the backbone of current cancer treatment – chemotherapy and radiotherapy regimens – with our discovery platform that delivers highly targeted antibody-drug conjugates (ADCs) and radioconjugates directly into cancer cells.

Our latest What Science Can Do article discusses the approaches we’re taking to increase the tumour specificity of ADCs and radioconjugates, making them better at homing in on cancer cells and reducing off-target effects.

As our ability to engineer our ADC and radioconjugate platforms evolve, so will our ability to develop precision medicines which target the right medicine, to the right patient, at the right time.

Read more